Insider Buying: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Buys $34,600.00 in Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) insider William Benton Jones acquired 20,000 shares of the stock in a transaction dated Monday, May 6th. The stock was bought at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the purchase, the insider now owns 153,773 shares in the company, valued at approximately $266,027.29. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Corvus Pharmaceuticals Stock Up 3.6 %

Shares of Corvus Pharmaceuticals stock opened at $2.03 on Friday. Corvus Pharmaceuticals, Inc. has a 12 month low of $1.05 and a 12 month high of $4.19. The business has a fifty day simple moving average of $1.77 and a 200 day simple moving average of $1.79. The stock has a market cap of $99.55 million, a PE ratio of -3.90 and a beta of 1.05.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Tuesday, March 19th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). Analysts expect that Corvus Pharmaceuticals, Inc. will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A hedge fund recently raised its stake in Corvus Pharmaceuticals stock. Towerview LLC grew its stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 67.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 342,478 shares of the company’s stock after buying an additional 137,478 shares during the quarter. Corvus Pharmaceuticals accounts for about 0.3% of Towerview LLC’s investment portfolio, making the stock its 18th biggest holding. Towerview LLC owned about 0.70% of Corvus Pharmaceuticals worth $500,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on CRVS. Mizuho reiterated a “neutral” rating and set a $3.50 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th. Oppenheimer lifted their target price on Corvus Pharmaceuticals from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.